SDS Optic S.A. is a company listed on NewConnect that develops their own technological platform inPROBE® for diagnosing cancers and infectious diseases in real time, and for monitoring health status. On 3 January 2023 the company signed a contract for advising in finding a strategic partner interested in commercialisation of the platform with the renown Clairfield International from New York, who will be responsible for identifying and selecting potential purchasers and for attracting their attention to the platform.
The partner’s operations will involve market research of and contact with global companies from the healthcare sector, with a particular focus on big pharma and big medtech. At a later stage, Clairfield will support the Company in the organisation of the due diligence process, shaping the negotiation strategy and final talks associated with drawing up a contract for the commercialisation of inPROBE®. The contract provides for the option to scale into other applications, license and purchases of selected applications of the technology.
– We are very glad that we have the opportunity to advise SDS Optic, the award-winning company developing inPROBE®, a breakthrough diagnostic technology used in oncology and medicine. SDS Optic have achieved a plethora of milestones towards commercialisation, and their technology has breakthrough potential both in oncological diagnostics and in innovative medication, thanks mainly to their significantly higher sensitivity and effectiveness. We are very happy that we will be able to support the SDS Optic team in attracting the interest of potential partners and in building the commercial success of inPROBE® – says Crosby O’Hare, Founder and Managing Partner at Clairfield International.
The co-operation is scheduled to commence on 1 February 2023, in 3 stages:
– Clairfield International is a leading global transaction advisor. Thanks to their experience in medical technologies and biotechnology, they bring to our commercialisation process of inPROBE® extensive expertise and relationship with the leading companies in the world. We have been working extensively with the Clairfield International team for over 3 years now, so we are familiar with each other. We have had many productive meetings, both at the Company’s registered office and in New York, which have allowed Clairfield to get to know our breakthrough technology and choose the best time to start a large-scale cooperation. We are extremely happy that we have got to a place where we can clearly say that this is the right moment, and to begin active endeavours in finding partners for commercialisation. Clairfield brings contacts, knowledge and experience in transactions in medical and pharmaceutical technologies, and their recent partnership contract with Yamada Consulting Group, a leading company providing transaction advisory services in Japan and Southeast Asia, accelerates our targets of finding a partner across potentially many markets. It should be emphasised that the best global concerns dealing with endoscopic technologies have their registered offices in Asia. We declare our full readiness and openness to facilitate making this process as smooth as possible, and achieve common success in the commercialisation of inPROBE® – says Mateusz Sagan, CEO at SDS Optic S.A.
– We can be sure that we have acquired extensive knowledge and understanding of inPROBE®, its stage of development, and can provide timely support for the most attractive transactions for SDS Optic and its shareholders. We appreciate the regular contact and communication we have maintained with SDS Optic over the past 3 years. We are confident that Clairfield is going to be a great advisor and advocate of all these years of hard work achieved by SDS Optic in getting to this important moment. We are proud that we have become a part of this team – says Edward Grey, Managing Director at Clairfield.
____________________________________________Clairfield International is a global company providing corporate finance services, mainly fusions and takeovers, for international corporations and financial investors. The advisors focus on the mid-market, executing transactions of up to EUR 500 million (enterprise value). The company is among the top twenty financial advisors in the world and ranks 7th in healthcare transactions, acc. to the Global Mid-Market M&A Review list prepared by Refinitiv. Clairfield employs about 300 specialists in 25 countries, and over the last 5 years has taken part in over 700 transactions with a total of EUR 25 billion. In November 2022, Clairfield signed a strategic contract with Yamada Consulting Group, one of the largest and most famous transaction advisory companies in Japan and Southeast Asia. As part of their transactions in the healthcare sector, Clairfield is developing their competencies around biotechnology, pharmacy, medical devices, supplies, hospitals, clinics, as well as laboratory services and equipment. As part of their biotechnological projects and medical devices, Clairfield has special experience in diagnostics and molecular therapeutics.
